Overactive Bladder - Results from #740

[Yun's optimized pelvic floor training therapy for idiopathic moderate overactive bladder with sexual dysfunction in young and middle-aged women]. April 4, 2020

Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis. April 4, 2020

Is there enough evidence to justify the use of laser and other thermal therapies in female lower urinary tract dysfunction? Report from the ICI-RS 2019. April 4, 2020

The Brazilian Portuguese version of the ICIQ-OABqol: cross-cultural adaptation and reliability. March 29, 2020

A multicenter cross-sectional study on the prevalence of overactive bladder and its impacts on the quality of life in gynecologic outpatients. March 29, 2020

The effect of a sharp increase in estrogen levels on OVERACTIVE BLADDER symptoms in women undergoing ovulation induction. March 29, 2020

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan. March 29, 2020

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A. March 29, 2020

NO-releasing nanoparticles ameliorate detrusor overactivity in transgenic sickle cell mice via restored NO/ROCK signaling. March 29, 2020

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). March 23, 2020

A pilot study to investigate the associations of urinary concentrations of urinary NO, ATP and derivatives with overactive bladder symptom severity. March 23, 2020

Quality of life and treatment persistence evaluation in Spanish patients treated with mirabegron. Results of the BELIEVE study. March 23, 2020

Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. March 23, 2020

Transcutaneous Electrical Spinal Cord Neuromodulator (TESCoN) Improves Symptoms of Overactive Bladder. March 16, 2020

International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. March 15, 2020

Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis. March 15, 2020

New Clinical Trial Examines a Potential Noninvasive Solution for Overactive Bladders March 11, 2020

Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder March 10, 2020

8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. March 9, 2020

Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. March 8, 2020

Page 38 of 122